Podcast
MSL Talk: Tom Caravela, Donnie Wooten
How to Develop IDPs Individual Development Plans and Road Maps for Career Development
Summary
In this episode, Tom Caravela is joined by Elaine Nadeau to delve into the realm of field medical excellence and the significance of Individual Development Plans (IDPs). Elaine shares her career journey and transition into this field, highlighting the role of IDPs in fostering career growth. The discussion covers how to initiate an IDP, the process of crafting one, and examples of professional development activities. The episode emphasizes the manager's role and mentorship, distinguishing IDPs from performance reviews, and maintaining their relevance, especially during COVID. Elaine offers valuable advice for MSLs on professional growth, concluding with encouraging words and a call to subscribe.
My guest today is Elaine Nadeau, Director Field Excellence at EMD Serono. We discuss how MSLs can Develop IDPs (Individual Development Plans) and Road Maps for Career Development.
In this episode we discuss:
- Who is Elaine and what she does
- How she got into the medical affairs
- Her role in Field Medical Excellence
- What is IDP and its importance
- MSLs starting on their own IDP
- The timeframe in creating the plan
- The pre-work and self-reflection of IDP
- Examples of professional development activities
- The manager’s involvement and role
- The different contributions of a coach versus a mentor
- New skills mandatory for MSLs during COVID
- Elaine’s advice for MSLs and MSL Leaders as we look to the future
Field Medical Excellence, Individual Development Plans, Career Growth for MSLs, Professional Development Activities, Medical Affairs Mentorship
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Donnie Wooten
Podcast
MSL Talk: Tom Caravela
Gratitude: An absolute MUST for career advancement
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary